Exscientia (NASDAQ:EXAI) Shares Gap Down to $4.95

Shares of Exscientia plc (NASDAQ:EXAI) gapped down before the market opened on Thursday . The stock had previously closed at $4.95, but opened at $4.80. Exscientia shares last traded at $4.77, with a volume of 128,542 shares trading hands.

Analysts Set New Price Targets

Separately, Morgan Stanley restated an “equal weight” rating and set a $7.00 target price on shares of Exscientia in a report on Monday, April 22nd.

Exscientia Trading Down 0.8 %

The company has a 50 day moving average of $5.01 and a two-hundred day moving average of $5.76. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.22 and a current ratio of 6.30.

Exscientia (NASDAQ:EXAI) last released its earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. The company had revenue of $3.10 million during the quarter, compared to analysts’ expectations of $41.63 million. Exscientia had a negative net margin of 666.80% and a negative return on equity of 34.59%. On average, equities research analysts forecast that Exscientia plc will post -1.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Exscientia

Several hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in Exscientia by 112.1% during the 1st quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after purchasing an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Exscientia by 359.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after buying an additional 4,104 shares during the last quarter. Rathbones Group PLC acquired a new position in Exscientia in the 3rd quarter worth approximately $47,000. Tocqueville Asset Management L.P. purchased a new position in Exscientia during the 3rd quarter worth approximately $58,000. Finally, Walled Lake Planning & Wealth Management LLC acquired a new stake in Exscientia during the 4th quarter valued at approximately $64,000. 41.58% of the stock is owned by institutional investors and hedge funds.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.